Precision BioSciences, Inc. announced that it expects to receive funding from TG Therapeutics, Inc.
On the same day, the company issued 2,920,816 common shares at a price of $0.77 per share for gross proceeds of $2,249,028.32 in its first tranche. The company will also receive an additional $2,500,000 within 11 months at 100% premium to the then 30-day VWAP prior to purchase.